Active substance
Quetiapine
- SFDA 92
- US FDA 42
- Health Canada 93
- US price lines 13
- NHS prices 14
- WHO EML 2
- Safety 7
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ADAZIO 100 mg film-coated tablet | 100 mg | Film-coated tablet · Oral use | 60 Blister | SAR 75.95 | Generic · Prescription | RIYADH PHARMA | Valid |
| ADAZIO 200 mg film-coated tablet | 200 mg | Film-coated tablet · Oral use | 60 Blister | SAR 151.90 | Generic · Prescription | RIYADH PHARMA | Valid |
| ADAZIO 25 mg film-coated tablet | 25 mg | Film-coated tablet · Oral use | 20 Blister | SAR 22.20 | Generic · Prescription | RIYADH PHARMA | Valid |
| ADAZIO 300 mg film-coated tablet | 300 mg | Film-coated tablet · Oral use | 30 Blister | SAR 113.95 | Generic · Prescription | RIYADH PHARMA | Valid |
| ATAPINA 100MG FILM COATED TABLET | 100 mg | Film-coated tablet · Oral use | 60 Blister | SAR 93.75 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| ATAPINA 200MG FILM COATED TABLET | 200 mg | Film-coated tablet · Oral use | 60 Blister | SAR 187.55 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| ATAPINA 25MG FILM COATED TABLET | 25 mg | Film-coated tablet · Oral use | 20 Blister | SAR 27.40 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| ATAPINA 300MG FILM COATED TABLET | 300 mg | Film-coated tablet · Oral use | 30 Blister | SAR 140.65 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| Adazio | 25 mg | Film-coated tablet · Oral use | 30 Blister | SAR 33.30 | Generic · Prescription | RIYADH PHARMA | Valid |
| ESPERAL 100 mg Film Coated Tablet | 100 mg | Film-coated tablet · Oral use | 60 Blister | SAR 46.90 | Generic · Prescription | DAR ALDAWA | Valid |
| ESPERAL 200 mg Film Coated Tablet | 200 mg | Film-coated tablet · Oral use | 60 Blister | SAR 87.00 | Generic · Prescription | DAR ALDAWA | Valid |
| ESPERAL 25 mg Film Coated Tablet | 25 mg | Film-coated tablet · Oral use | 60 Blister | SAR 19.90 | Generic · Prescription | DAR ALDAWA | Valid |
| ESPERAL 300 mg Film Coated Tablet | 300 mg | Film-coated tablet · Oral use | 30 Blister | SAR 71.40 | Generic · Prescription | DAR ALDAWA | Valid |
| Phreno XR | 400 mg | Prolonged-release tablet · Oral use | 30 Blister | SAR 88.90 | Generic · Prescription | Med City Pharma | Valid |
| Phreno XR | 400 mg | Prolonged-release tablet · Oral use | 60 Blister | SAR 177.80 | Generic · Prescription | Med City Pharma | Valid |
| Phreno XR | 300 mg | Prolonged-release tablet · Oral use | 30 Blister | SAR 56.15 | Generic · Prescription | Med City Pharma | Valid |
| Phreno XR | 300 mg | Prolonged-release tablet · Oral use | 60 Blister | SAR 112.35 | Generic · Prescription | Med City Pharma | Valid |
| Phreno XR | 200 mg | Prolonged-release tablet · Oral use | 30 Blister | SAR 41.40 | Generic · Prescription | Med City Pharma | Valid |
| Phreno XR | 200 mg | Prolonged-release tablet · Oral use | 60 Blister | SAR 67.70 | Generic · Prescription | Med City Pharma | Valid |
| Phreno XR | 50 mg | Prolonged-release tablet · Oral use | 30 Blister | SAR 13.20 | Generic · Prescription | Med City Pharma | Valid |
| Phreno XR | 50 mg | Prolonged-release tablet · Oral use | 60 Blister | SAR 26.40 | Generic · Prescription | Med City Pharma | Valid |
| QATPEN 100MG F.C.TABLET | 100 mg | Film-coated tablet · Oral use | 30 Blister | SAR 34.15 | Generic · Prescription | DAMMAM PHARMA | Valid |
| QATPEN 150MG F.C.TABLET | 150 mg | Film-coated tablet · Oral use | 30 Blister | SAR 51.25 | Generic · Prescription | DAMMAM PHARMA | Valid |
| QATPEN 200MG F.C.TABLET | 200 mg | Film-coated tablet · Oral use | 30 Blister | SAR 68.35 | Generic · Prescription | DAMMAM PHARMA | Valid |
| QATPEN 25MG F.C.TABLET | 25 mg | Film-coated tablet · Oral use | 30 Blister | SAR 29.95 | Generic · Prescription | DAMMAM PHARMA | Valid |
67 more — full table
Indications — CHI Daman Drug Formulary
ACUTE BIPOLAR I DEPRESSION; ACUTE MANIA; ALZHEIMER / DEMENTIA; ANXIETY DISORDERS; ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD); AUTISM SPECTRUM DISORDER; BIPOLAR I DISORDER MAINTENANCE; BIPOLAR II DISORDER; DEPRESSION; MENSTRUAL DISORDERS; SCHIZOPHRENIA; TOURETTE SYNDROME
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| SEROQUEL | EQ 25MG BASE; EQ 100MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE; EQ 50MG BASE | tablet · oral | CHEPLAPHARM | Prescription | 26 Sep 1997 |
| SEROQUEL XR | EQ 50MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE; EQ 150MG BASE | tablet, extended release · oral | CHEPLAPHARM | Prescription | 17 May 2007 |
| SEROQUEL XR | 50MG; 200MG; 300MG; 400MG | tablet, extended release · oral | CHEPLAPHARM ARZNEIMITTEL GMBH | Prescription | 15 Nov 2007 |
| QUETIAPINE FUMARATE | EQ 25MG BASE; EQ 50MG BASE; EQ 100MG BASE; EQ 150MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE | tablet · oral | RISING | Prescription | 27 Mar 2012 |
| QUETIAPINE FUMARATE | EQ 25MG BASE; EQ 50MG BASE; EQ 100MG BASE; EQ 150MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE | tablet · oral | TEVA PHARMS | Prescription | 27 Mar 2012 |
| QUETIAPINE FUMARATE | EQ 25MG BASE | tablet · oral | HIKMA PHARMS | Prescription | 27 Mar 2012 |
| QUETIAPINE FUMARATE | EQ 50MG BASE; EQ 100MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE | tablet · oral | HIKMA PHARMS | Prescription | 27 Mar 2012 |
| QUETIAPINE FUMARATE | EQ 25MG BASE; EQ 50MG BASE; EQ 100MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE | tablet · oral | SCIEGEN PHARMS | Prescription | 27 Mar 2012 |
| QUETIAPINE FUMARATE | EQ 25MG BASE; EQ 50MG BASE; EQ 100MG BASE; EQ 150MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE | tablet · oral | AUROBINDO PHARMA LTD | Prescription | 27 Mar 2012 |
| QUETIAPINE FUMARATE | EQ 25MG BASE; EQ 50MG BASE; EQ 100MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE | tablet · oral | LUPIN LTD | Prescription | 27 Mar 2012 |
| QUETIAPINE FUMARATE | EQ 25MG BASE; EQ 50MG BASE; EQ 100MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE | tablet · oral | ACCORD HLTHCARE | Prescription | 27 Mar 2012 |
| QUETIAPINE FUMARATE | EQ 25MG BASE; EQ 50MG BASE; EQ 100MG BASE; EQ 150MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE | tablet · oral | ALKEM LABS LTD | Prescription | 12 Feb 2013 |
| QUETIAPINE FUMARATE | EQ 25MG BASE; EQ 50MG BASE; EQ 100MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE | tablet · oral | UNICHEM | Prescription | 8 Mar 2016 |
| QUETIAPINE FUMARATE | EQ 25MG BASE; EQ 50MG BASE; EQ 100MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE | tablet · oral | MACLEODS PHARMS | Prescription | 17 May 2016 |
| QUETIAPINE FUMARATE | EQ 150MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE | tablet, extended release · oral | ACCORD HLTHCARE | Prescription | 1 Nov 2016 |
| QUETIAPINE FUMARATE | EQ 50MG BASE; EQ 150MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE | tablet, extended release · oral | PLATINUM | Prescription | 9 May 2017 |
| QUETIAPINE FUMARATE | EQ 50MG BASE; EQ 150MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE | tablet, extended release · oral | LUPIN | Prescription | 17 May 2017 |
| QUETIAPINE FUMARATE | EQ 150MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE | tablet, extended release · oral | MACLEODS PHARMS | Prescription | 29 Nov 2017 |
| QUETIAPINE FUMARATE | EQ 50MG BASE | tablet, extended release · oral | ACCORD HLTHCARE | Prescription | 29 Nov 2017 |
| QUETIAPINE FUMARATE | EQ 50MG BASE; EQ 150MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE | tablet, extended release · oral | AUROBINDO PHARMA | Prescription | 29 Nov 2017 |
| QUETIAPINE FUMARATE | EQ 50MG BASE; EQ 150MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE | tablet, extended release · oral | NOVAST LABS | Prescription | 29 Nov 2017 |
| QUETIAPINE FUMARATE | EQ 150MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE; EQ 50MG BASE | tablet, extended release · oral | SCIEGEN PHARMS | Prescription | 29 Nov 2017 |
| QUETIAPINE FUMARATE | EQ 150MG BASE; EQ 200MG BASE | tablet, extended release · oral | ALIGNSCIENCE PHARMA | Prescription | 28 Sep 2018 |
| QUETIAPINE FUMARATE | EQ 50MG BASE; EQ 150MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE | tablet, extended release · oral | PRINSTON INC | Prescription | 26 Apr 2022 |
| QUETIAPINE FUMARATE | EQ 25MG BASE; EQ 50MG BASE; EQ 100MG BASE; EQ 200MG BASE; EQ 300MG BASE; EQ 400MG BASE | tablet · oral | HETERO LABS LTD V | Prescription | 16 Jun 2022 |
17 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ACH-QUETIAPINE | 02387794 | 25 MG | TABLET (IMMEDIATE-RELEASE) · ORAL | ACCORD HEALTHCARE INC |
| ACH-QUETIAPINE | 02387808 | 100 MG | TABLET (IMMEDIATE-RELEASE) · ORAL | ACCORD HEALTHCARE INC |
| ACH-QUETIAPINE | 02387816 | 150 MG | TABLET (IMMEDIATE-RELEASE) · ORAL | ACCORD HEALTHCARE INC |
| ACH-QUETIAPINE | 02387824 | 200 MG | TABLET (IMMEDIATE-RELEASE) · ORAL | ACCORD HEALTHCARE INC |
| ACH-QUETIAPINE | 02387832 | 300 MG | TABLET (IMMEDIATE-RELEASE) · ORAL | ACCORD HEALTHCARE INC |
| ACH-QUETIAPINE FUMARATE XR | 02450860 | 50 MG | TABLET (EXTENDED-RELEASE) · ORAL | ACCORD HEALTHCARE INC |
| ACH-QUETIAPINE FUMARATE XR | 02450879 | 150 MG | TABLET (EXTENDED-RELEASE) · ORAL | ACCORD HEALTHCARE INC |
| ACH-QUETIAPINE FUMARATE XR | 02450887 | 200 MG | TABLET (EXTENDED-RELEASE) · ORAL | ACCORD HEALTHCARE INC |
| ACH-QUETIAPINE FUMARATE XR | 02450895 | 300 MG | TABLET (EXTENDED-RELEASE) · ORAL | ACCORD HEALTHCARE INC |
| ACH-QUETIAPINE FUMARATE XR | 02450909 | 400 MG | TABLET (EXTENDED-RELEASE) · ORAL | ACCORD HEALTHCARE INC |
| ACT QUETIAPINE | 02316080 | 25 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| ACT QUETIAPINE | 02316099 | 100 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| ACT QUETIAPINE | 02316110 | 200 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| ACT QUETIAPINE | 02316129 | 300 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| AG-QUETIAPINE FUMARATE | 02516934 | 25 MG | TABLET (IMMEDIATE-RELEASE) · ORAL | ANGITA PHARMA INC. |
| AG-QUETIAPINE FUMARATE | 02516942 | 100 MG | TABLET (IMMEDIATE-RELEASE) · ORAL | ANGITA PHARMA INC. |
| AG-QUETIAPINE FUMARATE | 02516950 | 200 MG | TABLET (IMMEDIATE-RELEASE) · ORAL | ANGITA PHARMA INC. |
| AG-QUETIAPINE FUMARATE | 02516969 | 300 MG | TABLET (IMMEDIATE-RELEASE) · ORAL | ANGITA PHARMA INC. |
| APO-QUETIAPINE FUMARATE | 02501643 | 100 MG | TABLET (IMMEDIATE-RELEASE) · ORAL | APOTEX INC |
| APO-QUETIAPINE XR | 02457245 | 200 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| APO-QUETIAPINE XR | 02457253 | 300 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| AURO-QUETIAPINE | 02390205 | 25 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-QUETIAPINE | 02390213 | 100 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-QUETIAPINE | 02390248 | 200 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-QUETIAPINE | 02390256 | 300 MG | TABLET · ORAL | AURO PHARMA INC |
68 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | QUETIAPINE 150 MG TABLET | $1.23864 | per EA | 23 Sep 2026 |
| US NADAC | QUETIAPINE ER 150 MG TABLET | $0.18361 | per EA | 23 Sep 2026 |
| US NADAC | QUETIAPINE ER 200 MG TABLET | $0.21991 | per EA | 23 Sep 2026 |
| US NADAC | QUETIAPINE ER 300 MG TABLET | $0.27174 | per EA | 23 Sep 2026 |
| US NADAC | QUETIAPINE ER 400 MG TABLET | $0.31743 | per EA | 23 Sep 2026 |
| US NADAC | QUETIAPINE ER 50 MG TABLET | $0.11917 | per EA | 23 Sep 2026 |
| US NADAC | QUETIAPINE FUMARATE 100 MG TAB | $0.0483 | per EA | 23 Sep 2026 |
| US NADAC | QUETIAPINE FUMARATE 200 MG TAB | $0.08962 | per EA | 23 Sep 2026 |
| US NADAC | QUETIAPINE FUMARATE 25 MG TAB | $0.02147 | per EA | 23 Sep 2026 |
| US NADAC | QUETIAPINE FUMARATE 300 MG TAB | $0.12747 | per EA | 23 Sep 2026 |
| US NADAC | QUETIAPINE FUMARATE 400 MG TAB | $0.16163 | per EA | 23 Sep 2026 |
| US NADAC | QUETIAPINE FUMARATE 50 MG TAB | $0.02817 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Quetiapine 100mg tablets | £2.13 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Quetiapine 150mg modified-release tablets | £113.10 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Quetiapine 150mg tablets | £2.36 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Quetiapine 200mg modified-release tablets | £113.10 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Quetiapine 200mg tablets | £2.70 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Quetiapine 20mg/ml oral suspension sugar free | £223.18 | 150 ml | 1 Oct 2026 |
| NHS Drug Tariff | Quetiapine 25mg tablets | £1.05 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Quetiapine 300mg modified-release tablets | £170.00 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Quetiapine 300mg tablets | £3.17 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Quetiapine 400mg modified-release tablets | £226.20 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Quetiapine 400mg tablets | £25.00 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Quetiapine 50mg modified-release tablets | £67.66 | 60 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 24.1. Medicines for psychotic disorders · core
Therapeutic equivalent to risperidone for Schizophrenia or other primary psychotic disorders - 24.2.2. Medicines for bipolar disorders · core
Bipolar or related disorders
Oral > Solid > tablet: 25 mg (immediate-release); 100 mg (immediate-release); 150 mg (immediate-release); 200 mg (immediate-release); 300 mg (immediate-release); 50 mg (modified-release); 150 mg (modified-release); 200 mg (modified-release); 300 mg (modified-release); 400 mg (modified-release)
Safety signals and safety-related labeling changes
- US FDA 22 Jan 2025 SEROQUEL — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Jan 2025 SEROQUEL XR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 11 Jun 2015 PRAC signal: Acute renal failure
Action for MAH: update of the product information: No - EMA PRAC 6 Nov 2014 PRAC signal: Acute renal failure
Action for MAH: update of the product information: No - EMA PRAC 8 May 2014 PRAC signal: Possible misuse and abuse
Action for MAH: update of the product information: No - EMA PRAC 6 Mar 2014 PRAC signal: Suicidality in major depressive disorder (MDD) patients
Action for MAH: update of the product information: No - EMA PRAC 10 Oct 2013 PRAC signal: Suicidality in major depressive disorder (MDD) patients
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.